New Delhi: The US health regulator has approved Mylan’s cancer treating biosimilar Fulphila co-developed with Biocon, the companies said today. Fulphila is the first US Food and Drug Administration ( USFDA) approved biosimilar to Neulasta and the second biosimilar from Mylan and Biocon’s joint portfolio approved in the US, they said in a joint statement.
LONDON (Reuters) – Cut-price copies of expensive biotech drugs promise to slash the cost of treating serious diseases, including cancer, in rich and poor countries alike – but uneven regulation has created a lopsided market.
A patent fight has already delayed Sandoz’ biosimilar version of Amgen’s anti-inflammatory blockbuster Enbrel. And now, it looks as if Sandoz will have to wait a little longer for a clear shot at the launch.
From drug pricing and ‘biosimilars’ to opioids and culture – a wrap and podcast from the J.P. Morgan Healthcare Conference – San Francisco Business Times
It could be weeks or a year before the deals that biotech executives and financiers started at last week’s 36th J.P. Morgan Healthcare Conference come to fruition. But here’s a quick wrap – and a BioFlash podcast – of tidbits from Bay Area companies: BAGGING OPIOIDS McKesson Corp.